Abstract: Provided is an oil leakage repairing material, wherein the oil leakage repairing material is a curable composition, oil absorption of the oil leakage repairing material before curing is 100% or greater, and oil absorption of the oil leakage repairing material after curing is 50% or less.

Abstract: Disclosed is a cell classification method, to be executed by an analyzer, for classifying cells contained in a specimen, including: preparing a first measurement sample by treating a specimen under a first preparation condition; obtaining a first signal from the prepared first measurement sample; classifying, by using the first signal, cells contained in the first measurement sample; preparing a second measurement sample by treating the specimen under a second preparation condition different from the first preparation condition; obtaining a second signal from the prepared second measurement sample; classifying, by using the second signal, cells contained in the second measurement sample; and comparing a result of the cell classification performed by using the first signal and a result of the cell classification performed by using the second signal, with each other, and outputting an analysis result including a number of cells on the basis of a result of the comparison.

Abstract: A projector in an installation information acquisition method is installed in a real space, has a changeable projection direction, and projects a projection image based on a virtual image. The virtual image is an image in a case where an image arranged at a display position in a virtual space is viewed from a virtual installation position. The method includes first acquisition processing for acquiring positional information of three or more first adjustment points in the virtual space, projection processing for projecting, by the projector, an index image onto the real space, second acquisition processing for acquiring angle information of the projection direction with respect to a reference direction in a state where the index image matches three or more second adjustment points respectively corresponding to the three or more first adjustment points, and third acquisition processing for acquiring installation information based on the positional information and the angle information.

Abstract: A projection direction change device includes a mirror that reflects light emitted from a projection lens unit of a projector, a mirror support part that rotatably supports the mirror around a first axis and a second axis, a first drive part that rotary drives the mirror around the first axis, and a second drive part that rotary drives the mirror around the second axis. An intersecting point of the first and second axes is positioned closer to the projection lens unit than a geometric barycenter of the mirror is.

Abstract: A problem to be solved by the present invention is to provide a uremic toxin reducing agent, a total cholesterol reducing agent and a triglyceride reducing agent. The problem is solved by providing a uremic toxin reducing agent, a total cholesterol reducing agent and a triglyceride reducing agent, wherein each agent comprises Lactobacillus bacteria, Bifidobacterium bacteria or Bacteroides bacteria.

Abstract: A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

Abstract: An object of the present invention is to provide a low molecular weight compound having a prophylactic or therapeutic action on cancer. A compound of the following formula (1), a compound of the following formula (2), or the like can be administered by a method such as oral administration to prevent or treat cancers such as colorectal cancer.

Abstract: An object of the present invention is to provide an agent for enhancing fertilization function of a mammal sperm, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient, and a method for enhancing fertilization function of a mammal sperm and a method for preparing a mammal fertilized egg, which use a low molecular compound which can be produced relatively easily and inexpensively. An agent comprising one or more compounds selected from the group consisting of compounds of the following formula (I0), formula (II), and formula (III), and physiologically acceptable salts thereof when R3 is OH is used as an agent for enhancing fertilization function of a mammal sperm.

Abstract: A content generation method generates image content to be projected at a projection position in a real space by a projector. In a first acquisition process, space information regarding a virtual space corresponding to the real space is acquired. In a second acquisition process, display position information regarding a display position corresponding to the projection position in the virtual space is acquired. In a third acquisition process, reference position information regarding a reference position in the virtual space is acquired. In a generation process, an image including an object viewed from the reference position when the object is displayed at the display position in the virtual space is generated as the image content, based on the space information, the reference position information, and the display position information.

Abstract: It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

Abstract: A projection direction change device includes a mirror that reflects light emitted from a projection lens unit of a projector, a mirror support part that rotatably supports the mirror around a first axis and a second axis, a first drive part that rotary drives the mirror around the first axis, and a second drive part that rotary drives the mirror around the second axis. An intersecting point of the first and second axes is positioned closer to the projection lens unit than a geometric barycenter of the mirror is.

Abstract: It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when R3 represents OH.

Abstract: An image signal processing device receives image signals from source devices and outputs image signals via a plurality of communication paths. The image signal processing device includes a plurality of compression circuits, a transmission circuit and a path/compression-rate setting circuit. The plurality of compression circuits compress image signals to be transmitted via the plurality of communication paths. The transmission circuit outputs the image signals compressed. The path/compression-rate setting circuit, based on each data amount of the image signals received, determines a communication path for transmitting a part or the whole of each of the image signal, and sets a common compression rate for all of the plurality of compression circuits. The path/compression-rate setting circuit divides an image signal having a relatively large data amount, and assigns a part of the divided image signal to a communication path for transmitting an image signal having a relatively small data amount.

Abstract: A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

Abstract: An object of the present invention is to provide a biomarker capable of determining the onset risk or the stage of diabetic nephropathy (early-stage diabetic nephropathy in particular). Diabetic nephropathy is determined by measuring or quantitatively determining a concentration of phenyl sulfate or a salt thereof (a phenyl sulfate) contained in a biological sample, preferably plasma or urine, collected from a test subject to detect a phenyl sulfate. The present invention exhibits excellent effects particularly for stage determination for stage 1 (pre-nephropathy stage) to stage 3 (overt nephropathy stage), or for determination of onset risk of diabetic nephropathy (diabetic nephropathy at pre-nephropathy stage).

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

Abstract: Image display system 10 comprises: a plurality of display devices 111; an image processing unit for receiving input of a plurality of input video signals and generating an output video signal for each display device in accordance with a layout for the display devices from the input video signals; a pattern signal generation unit for generating pattern signals indicating a plurality of different test pattern images; a selector for receiving input of the output video signals and the pattern signals and selecting and outputting either the output video signals or the pattern signals; imaging device 120 for capturing an image of the test pattern images displayed on the respective display devices; and a control device 140 for analyzing the captured image captured by the imaging device and generating control information for controlling the image processing unit, based on analysis results.

Abstract: It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when R3 represents OH.

Abstract: An image signal processing device receives image signals from source devices and outputs image signals via a plurality of communication paths. The image signal processing device includes a plurality of compression circuits, a transmission circuit and a path/compression-rate setting circuit. The plurality of compression circuits compress image signals to be transmitted via the plurality of communication paths. The transmission circuit outputs the image signals compressed. The path/compression-rate setting circuit, based on each data amount of the image signals received, determines a communication path for transmitting a part or the whole of each of the image signal, and sets a common compression rate for all of the plurality of compression circuits. The path/compression-rate setting circuit divides an image signal having a relatively large data amount, and assigns a part of the divided image signal to a communication path for transmitting an image signal having a relatively small data amount.